Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells

BACKGROUND: Vemurafenib (VEM) is a commonly used inhibitor of papillary thyroid cancer (PTC) and melanoma with the BRAF(V600E) mutation; however, acquired resistance is unavoidable. The present study aimed to identify a potential target to reverse resistance. MATERIALS AND METHODS: A VEM-resistant P...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Suyuan, Huang, Yuxin, Li, Yuan, Gu, Qin, Jiang, Cuiping, Tao, Xiaoming, Sun, Jiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813165/
https://www.ncbi.nlm.nih.gov/pubmed/36331719
http://dx.doi.org/10.1007/s12020-022-03180-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813165/
https://www.ncbi.nlm.nih.gov/pubmed/36331719
http://dx.doi.org/10.1007/s12020-022-03180-y

Ejemplares similares